Was the topic of discussion by CEO Paul Ashton in his intial discussion utilizing this new format for CEO's (see news section). This is the thought process/ system that will take PSDV to the top of the drug delivery business and the one that I have been basing my outrageous claims of $40. dollar stock by 2015.My biggest and best hope is in the works.Thank you Paul,Bev and the whole team.
I'm fairly curious as to whether or not the new breakthrough designation from the FDA is on the table for pSivida. Seems to fit the bill in a lot of ways. I believe mick brought this possibility up a week ago or so.